Berenberg Bank Reaffirms “Buy” Rating for AstraZeneca (LON:AZN)

AstraZeneca (LON:AZN)‘s stock had its “buy” rating reissued by equities researchers at Berenberg Bank in a research report issued to clients and investors on Wednesday,London Stock Exchange reports. They currently have a GBX 140 ($1.80) price target on the biopharmaceutical company’s stock. Berenberg Bank’s price target would suggest a potential downside of 98.75% from the company’s current price.

AZN has been the subject of a number of other research reports. JPMorgan Chase & Co. reiterated an “overweight” rating on shares of AstraZeneca in a report on Wednesday, February 19th. Shore Capital reaffirmed a “buy” rating on shares of AstraZeneca in a research note on Friday, March 7th. Two research analysts have rated the stock with a hold rating and five have given a buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of GBX 7,542.80 ($97.11).

AstraZeneca Trading Down 0.1 %

Shares of LON:AZN traded down GBX 8 ($0.10) during trading hours on Wednesday, hitting £112.24 ($144.51). 16,843,158 shares of the company’s stock traded hands, compared to its average volume of 23,815,439. The firm has a market capitalization of £215.95 billion, a P/E ratio of 30.77, a price-to-earnings-growth ratio of 0.86 and a beta of 0.17. The business has a fifty day moving average price of £115.70 and a 200-day moving average price of £112.80. AstraZeneca has a 1 year low of GBX 9,670 ($124.50) and a 1 year high of £133.88 ($172.37). The company has a debt-to-equity ratio of 73.83, a current ratio of 0.93 and a quick ratio of 0.59.

AstraZeneca Company Profile

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.